Physician profile
Fernando Borrego
NPI 1548288277
$5,370.39
in general payments reported to CMS, 2019-2025
14 companies · $813 in 2025
The $813 reported for 2025 was more than what 76% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,036 · 2020: $325 · 2021: $1,048 · 2022: $466 · 2023: $776 · 2024: $907 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,495.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,364.78 | 2019-2025 | Epclusa, Biktarvy |
| Viiv Healthcare Company | $2,188.83 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Abbvie INC. | $216.39 | 2019-2025 | Mavyret |
| Horizon Therapeutics Plc | $171.66 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $158.42 | 2025 | Nuzyra |
| Teva Pharmaceuticals USA, INC. | $63.07 | 2023 | Uzedy |
| Indivior INC. | $43.30 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $41.17 | 2020-2022 | |
| Lundbeck LLC | $32.76 | 2021 | |
| Alkermes, INC. | $23.28 | 2019 | |
| Emd Serono, INC. | $20.63 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.90 | 2019 | |
| Melinta Therapeutics, LLC | $14.73 | 2019 | |
| Glaxosmithkline, LLC. | $11.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Borrego listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.